FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2131882149> ?p ?o ?g. }

• W2131882149 endingPage "2275" @default.
• W2131882149 startingPage "2275" @default.
• W2131882149 abstract "Tumor necrosis factor (TNF) plays an important role in host defense and tumor growth control. Therefore, anti-TNF antibody therapies may increase the risk of serious infections and malignancies.To assess the extent to which anti-TNF antibody therapies may increase the risk of serious infections and malignancies in patients with rheumatoid arthritis by performing a meta-analysis to derive estimates of sparse harmful events occurring in randomized trials of anti-TNF therapy.A systematic literature search of EMBASE, MEDLINE, Cochrane Library, and electronic abstract databases of the annual scientific meetings of both the European League Against Rheumatism and the American College of Rheumatology was conducted through December 2005. This search was complemented with interviews of the manufacturers of the 2 licensed anti-TNF antibodies.We included randomized, placebo-controlled trials of the 2 licensed anti-TNF antibodies (infliximab and adalimumab) used for 12 weeks or more in patients with rheumatoid arthritis. Nine trials met our inclusion criteria, including 3493 patients who received anti-TNF antibody treatment and 1512 patients who received placebo.Data on study characteristics to assess study quality and intention-to-treat data for serious infections and malignancies were abstracted. Published information from the trials was supplemented by direct contact between principal investigators and industry sponsors.We calculated a pooled odds ratio (Mantel-Haenszel methods with a continuity correction designed for sparse data) for malignancies and serious infections (infection that requires antimicrobial therapy and/or hospitalization) in anti-TNF-treated patients vs placebo patients. We estimated effects for high and low doses separately. The pooled odds ratio for malignancy was 3.3 (95% confidence interval [CI], 1.2-9.1) and for serious infection was 2.0 (95% CI, 1.3-3.1). Malignancies were significantly more common in patients treated with higher doses compared with patients who received lower doses of anti-TNF antibodies. For patients treated with anti-TNF antibodies in the included trials, the number needed to harm was 154 (95% CI, 91-500) for 1 additional malignancy within a treatment period of 6 to 12 months. For serious infections, the number needed to harm was 59 (95% CI, 39-125) within a treatment period of 3 to 12 months.There is evidence of an increased risk of serious infections and a dose-dependent increased risk of malignancies in patients with rheumatoid arthritis treated with anti-TNF antibody therapy. The formal meta-analysis with pooled sparse adverse events data from randomized controlled trials serves as a tool to assess harmful drug effects." @default.
• W2131882149 created "2016-06-24" @default.
• W2131882149 creator A5003542031 @default.
• W2131882149 creator A5011177296 @default.
• W2131882149 creator A5037961312 @default.
• W2131882149 creator A5052273654 @default.
• W2131882149 creator A5061691563 @default.
• W2131882149 creator A5085782112 @default.
• W2131882149 date "2006-05-17" @default.
• W2131882149 modified "2023-10-03" @default.
• W2131882149 title "Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies" @default.
• W2131882149 cites W1600790350 @default.
• W2131882149 cites W1782927085 @default.
• W2131882149 cites W1833163659 @default.
• W2131882149 cites W1891655359 @default.
• W2131882149 cites W1929330671 @default.
• W2131882149 cites W1970336778 @default.
• W2131882149 cites W1976290551 @default.
• W2131882149 cites W1979364075 @default.
• W2131882149 cites W1979933330 @default.
• W2131882149 cites W1980827798 @default.
• W2131882149 cites W1985763670 @default.
• W2131882149 cites W1989574614 @default.
• W2131882149 cites W1993515378 @default.
• W2131882149 cites W1995104906 @default.
• W2131882149 cites W1996472975 @default.
• W2131882149 cites W1999777294 @default.
• W2131882149 cites W2000183493 @default.
• W2131882149 cites W2005429018 @default.
• W2131882149 cites W2007929726 @default.
• W2131882149 cites W2013829686 @default.
• W2131882149 cites W2013890384 @default.
• W2131882149 cites W2014871413 @default.
• W2131882149 cites W2024006864 @default.
• W2131882149 cites W2026077821 @default.
• W2131882149 cites W2035451066 @default.
• W2131882149 cites W2035642138 @default.
• W2131882149 cites W2037882607 @default.
• W2131882149 cites W2039597867 @default.
• W2131882149 cites W2043979514 @default.
• W2131882149 cites W2045789990 @default.
• W2131882149 cites W2046628605 @default.
• W2131882149 cites W2058674147 @default.
• W2131882149 cites W2061743282 @default.
• W2131882149 cites W2061795568 @default.
• W2131882149 cites W2067874068 @default.
• W2131882149 cites W2081833623 @default.
• W2131882149 cites W2083434894 @default.
• W2131882149 cites W2085947993 @default.
• W2131882149 cites W2086721113 @default.
• W2131882149 cites W2086860754 @default.
• W2131882149 cites W2090819045 @default.
• W2131882149 cites W2094842594 @default.
• W2131882149 cites W2104388056 @default.
• W2131882149 cites W2114872119 @default.
• W2131882149 cites W2125435699 @default.
• W2131882149 cites W2126930838 @default.
• W2131882149 cites W2133541603 @default.
• W2131882149 cites W2133604058 @default.
• W2131882149 cites W2135626649 @default.
• W2131882149 cites W2142273705 @default.
• W2131882149 cites W2156996668 @default.
• W2131882149 cites W2157279567 @default.
• W2131882149 cites W2165431917 @default.
• W2131882149 cites W2168139737 @default.
• W2131882149 cites W2170952317 @default.
• W2131882149 cites W2319957449 @default.
• W2131882149 cites W2336588424 @default.
• W2131882149 cites W2412553269 @default.
• W2131882149 cites W2418358993 @default.
• W2131882149 cites W2438063247 @default.
• W2131882149 cites W2473041787 @default.
• W2131882149 cites W3146223861 @default.
• W2131882149 cites W62925436 @default.
• W2131882149 cites W46650105 @default.
• W2131882149 doi "https://doi.org/10.1001/jama.295.19.2275" @default.
• W2131882149 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16705109" @default.
• W2131882149 hasPublicationYear "2006" @default.
• W2131882149 type Work @default.
• W2131882149 sameAs 2131882149 @default.
• W2131882149 citedByCount "2293" @default.
• W2131882149 countsByYear W21318821492012 @default.
• W2131882149 countsByYear W21318821492013 @default.
• W2131882149 countsByYear W21318821492014 @default.
• W2131882149 countsByYear W21318821492015 @default.
• W2131882149 countsByYear W21318821492016 @default.
• W2131882149 countsByYear W21318821492017 @default.
• W2131882149 countsByYear W21318821492018 @default.
• W2131882149 countsByYear W21318821492019 @default.
• W2131882149 countsByYear W21318821492020 @default.
• W2131882149 countsByYear W21318821492021 @default.
• W2131882149 countsByYear W21318821492022 @default.
• W2131882149 countsByYear W21318821492023 @default.
• W2131882149 crossrefType "journal-article" @default.
• W2131882149 hasAuthorship W2131882149A5003542031 @default.
• W2131882149 hasAuthorship W2131882149A5011177296 @default.
• W2131882149 hasAuthorship W2131882149A5037961312 @default.
• W2131882149 hasAuthorship W2131882149A5052273654 @default.

• next